AstraZeneca started at buy at Goldman, which rates GSK a neutral

Goldman Sachs started coverage of AstraZeneca at buy as it rated rival GSK a neutral. https://www.marketwatch.com/story/astrazeneca-started-at-buy-at-goldman-which-rates-gsk-a-neutral-93c95b7f?mod=mw_rss_topstories